[Intravenously administered gamma-globulins in reactive hemaphagocytic syndrome. Multicenter study to assess their importance, by the immunoglobulins group of experts of CEDIT of the AP-HP].

Abstract

Reactive hemophagocytic syndrome is characterized by systemic proliferation and activation of benign hemophagocytic cells of the monocyte-macrophage lineage. Treatment should be directed to the etiology, but successful treatment with high-dose gamma-globulin has been reported, especially in viral-associated hemophagocytic syndrome. We report 17 patients, of which 9 had infection-associated hemophagocytic syndrome, all treated with high-dose gamma-globulin. High-dose gamma-globulins appear to be more effective in infection-associated hemophagocytic syndrome, with a mean dose of 1.6gm/kg for one or two cycles. A multicentric randomized study is required to evaluate high-dose gamma-globulin in the treatment of reactive hemophagocytic syndrome.

• Authors: C Larroche, F Bruneel, M H André, B Bader-Meunier, A Baruchel, B Tribout, T Genereau, P Zunic, Comité d'Evaluation et de Diffusion des Innovation Technologiques (CEDIT)
• Journal: Annales de medecine interne (Ann Med Interne (Paris)) Vol. 151 Issue 7 Pg. 533-539 (Nov 2000) ISSN: 0003-410X [Print] France
• Vernacular Title: Les immunoglobulines intra-veineuses dans les syndromes d'activation macrophagique secondaires. Etude multicentrique évaluant leur intérêt, pour le groupe d'experts sur les immunoglobulines du CEDIT de l'AP-HP.
• PMID: 11139652 (Publication Type: English Abstract, Journal Article, Multicenter Study, Review)

Chemical References

• Immunoglobulins, Intravenous

Topics

• Adolescent
• Adult
• Aged
• Child, Preschool
• Female
• Histiocytosis, Non-Langerhans-Cell (etiology, therapy)
• Humans
• Immunity, Cellular
• Immunoglobulins, Intravenous (therapeutic use)
• Infant
• Male
• Middle Aged
• Retrospective Studies